BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/24/2023 9:31:05 AM | Browse: 375 | Download: 997
 |
Received |
|
2022-11-19 01:49 |
|
Peer-Review Started |
|
2022-11-19 13:08 |
|
First Decision by Editorial Office Director |
|
2023-02-01 23:14 |
|
Return for Revision |
|
2023-02-02 17:12 |
|
Revised |
|
2023-03-13 23:16 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-04-11 03:00 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-04-12 03:04 |
|
Articles in Press |
|
2023-04-12 03:04 |
|
Edit the Manuscript by Language Editor |
|
2023-04-10 23:55 |
|
Typeset the Manuscript |
|
2023-05-17 07:50 |
|
Publish the Manuscript Online |
|
2023-05-24 09:31 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
Copyright: © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Current and novel modalities for management of chronic hepatitis B infection
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Iman Ibrahim Salama, Samia M Sami, Somaia I Salama, Ghada A Abdel-Latif, Fatma A Shaaban, Walaa A Fouad, Aida M Abdelmohsen and Hala M Raslan |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Iman Ibrahim Salama, MD, Academic Research, Research Scientist, Department of Community Medicine Research, National Research Center, El bouhoth street, Giza 12411, Dokki, Egypt. salamaiman@yahoo.com |
| Key Words |
Current modalities; Novel modalities; Management; Chronic hepatitis B infection; Direct acting antiviral therapy; Immunotherapy; Therapeutic vaccination |
| Core Tip |
Chronic hepatitis B virus (HBV) infection is a result of immune tolerance and the presence of covalently closed circular DNA and the integrated HBV. The currently approved therapies are nucleos(t)ide analogues, interferon-alpha, and pegylated-interferon-alpha, with functional cure achieved in < 10% of patients. Disruption of the interaction between HBV or the host immune system can lead to HBV reactivation. Novel therapies include direct acting antivirals and immunomodulators. Immunomodulators may enhance/restore innate and adaptive immunity against HBV (as toll-like-receptors and retinoic acid inducible gene-1 agonist), checkpoint inhibitors, therapeutic HBV vaccines, and genetically engineered T cells to restore T cell function. |
| Publish Date |
2023-05-24 09:31 |
| Citation |
Salama II, Sami SM, Salama SI, Abdel-Latif GA, Shaaban FA, Fouad WA, Abdelmohsen AM, Raslan HM. Current and novel modalities for management of chronic hepatitis B infection. World J Hepatol 2023; 15(5): 585-608 |
| URL |
https://www.wjgnet.com/1948-5182/full/v15/i5/585.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v15.i5.585 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
